Thymogen
Also known as: L-Glu-L-Trp, Glu-Trp, EW dipeptide, IM862 (related dipeptide; see notes)
Synthetic thymic immunomodulatory dipeptide (thymomimetic)
What it is
Thymogen is a synthetic thymic dipeptide studied for its immune-stimulating and antioxidant properties, with potential applications in liver protection and immune deficiency. It works by activating key immune cells to strengthen the body's defense responses. No FDA-approved use; primarily studied in Russian research with limited independent replication.
The scientific side
Thymogen (L-Glu-L-Trp) is a dipeptide originally isolated from thymus homogenate with immunostimulatory properties. Published studies indicate it binds with high affinity to murine peritoneal macrophages and thymocytes (inhibiting binding of the related dipeptide bestim), and is characterised as an immunostimulant in contrast to its D-enantiomer-based counterpart Thymodepressin, which is immunosuppressive — illustrating reciprocal biological activity based on chirality. It has been described as a modulator of cellular immunity, a thymomimetic, and an interferon inducer in the reviewed literature. The glutamic acid–tryptophan scaffold has also been shown to inhibit angiotensin-converting enzyme (ACE) activity in endothelial cells and to block angiotensin I-induced vasoconstriction ex vivo and in vivo, though this ACE-inhibitory work was conducted primarily with the EW peptide in a comparative context. Thymogen analogues have demonstrated antioxidant and hepatoprotective effects in animal models of toxic liver injury.
Class: Synthetic thymic immunomodulatory dipeptide (thymomimetic)
Administration & storage
- Administration
- Intranasal instillation (PMID: 21957588)Intranasal daily administration (PMID: 17879948)Intragastric administration in animal model (PMID: 37861903)In vitro cell culture incubation (PMID: 35408963PMID: 18365736PMID: 18428206)
- Storage
- No storage conditions for Thymogen are described in the reviewed abstracts.
- Cautions
- Human safety data are limited to a small number of clinical studies; no significant toxicities were reported in the IM862 intranasal RCT and immunomodulatory therapy was well tolerated in the pre-surgical elderly cohort, but long-term safety data are not available from the reviewed literature.,Thymogen is highly hydrophilic with low membrane permeability in its native form, which limits oral bioavailability; novel conjugates designed to improve absorption have not yet been clinically validated.,The peptide's biological activity is highly dependent on stereochemistry — the D-enantiomer-based Thymodepressin has immunosuppressive rather than immunostimulatory effects, underscoring the importance of confirmed peptide identity and purity in any preparation.,No clinical pharmacokinetic or pharmacodynamic data in humans are reported in the reviewed abstracts.,Sterile technique should be observed for any injectable or intranasal preparation to prevent contamination.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Immunomodulation / immunostimulation Mixed
- Double-blind, randomized, placebo-controlled RCT in elderly patients undergoing surgery for abdominal/retroperitoneal tumors. Thymogen (100 mg intranasal, once daily for 7 days pre-operatively) restored structural and functional parameters of cellular immunity and significantly reduced post-operative complications. PMID 21957588 Smirnov VS et al. Advances in gerontology (2011)
- In vitro study in THP-1 monocyte/macrophage cell line: Thymogen dipeptide modulated key proliferative patterns (increased tyrosine phosphorylation of mitogen-activated cytoplasmic kinases), inhibited LPS-stimulated TNF and IL-6 expression, and reduced monocyte adhesion to activated endothelial cells. PMID 35408963 Avolio F et al. International journal of molecular sciences (2022)
- Review identifying Thymogen among interferon inducers used clinically in former socialist countries, with antiviral, antibacterial, antitumor, and anti-inflammatory application contexts noted. PMID 19355963 Silin DS et al. Current pharmaceutical design (2009)
- Review summarizing long-term clinical studies of peptide bioregulators including Thymogen for disease prevention and treatment across age groups, including use as a geroprotector. PMID 24003726 Khavinson VKh et al. Advances in gerontology (2013)
- Antioxidant and hepatoprotective effects Animal studies only
- In a CCl4-induced acute toxic hepatopathy model, intragastric Thymogen suppressed oxidative peroxidation, reduced malondialdehyde, and stimulated hepatocyte regeneration. Structural analogues with D-Ala additions showed more pronounced effects than Thymogen alone. PMID 37861903 Chulanova AA et al. Bulletin of experimental biology and medicine (2023)
- Chirality-based regulation of immune homeostasis (immunostimulation vs. immunosuppression) Mixed
- Review describing Thymogen (L-Glu-L-Trp) as an immunostimulant and its D-enantiomer-based counterpart Thymodepressin (D-Glu(D-Trp)) as an immunosuppressor, representing the first example of reciprocal biological activity from enantiomeric peptide drugs. PMID 38732260 Deigin V et al. International journal of molecular sciences (2024)
- Describes Thymogen (Glu-Trp) as developed from the most active dipeptide separated from thymus homogenate in the 1980s. Inversion of amino acid optical form endows dipeptides with suppressor properties, confirming the immunostimulant character of the all-L form. PMID 32058926 Deigin V et al. International immunopharmacology (2020)
- ACE inhibition and antihypertensive vascular effects (EW dipeptide) Mixed
- Glutamic acid-tryptophan (EW) dipeptide demonstrated ACE inhibitory activity in HUVECs and blocked angiotensin I-induced vasoconstriction in rat aorta ex vivo and in vivo. IW had the highest efficacy among tryptophan-containing peptides tested; EW was intermediate. PMID 28102435 Khedr S et al. European journal of nutrition (2018)
- Oral bioavailability enhancement (lipid/glycosyl conjugation of L-Glu-L-Trp) In vitro only
- L-Glu-L-Trp is described as highly hydrophilic with low membrane permeability; conjugation with lipoamino acids and sugar moieties significantly increased enzymatic stability and apparent permeability in Caco-2 models. One conjugate released the parent dipeptide after penetrating Caco-2 monolayers. Initial in vivo abso PMID 18428206 Bergeon JA et al. Biopolymers (2008)
- Receptor binding characterisation (macrophages and thymocytes) In vitro only
- Thymogen (L-Glu-L-Trp) competed with tritium-labeled bestim (gamma-D-Glu-L-Trp) for binding to murine peritoneal macrophages (Ki 0.9 ± 0.1 nM) and thymocytes (Ki 1.1 ± 0.1 nM), suggesting shared or overlapping binding sites on immune cell membranes. PMID 18365736 Kolobov AA et al. Bioorganicheskaia khimiia (2008)
- Psychiatric/neurological adjunct therapy (obsessive-compulsive and tic disorders) Human observational
- In 84 patients with obsessive-compulsive neurosis and generalized tic disease, complex therapy including Thymogen, mexidol, and hyperbaric oxygenation showed significantly higher efficacy than traditional pharmacotherapy. Immune and endocrine dysfunction was noted in these patients. PMID 20517227 Podsevatkin VG et al. Zhurnal nevrologii i psikhiatrii (2010)
- Dental and maxillofacial disease management (bioregulatory therapy) Human observational
- Review describing use of thymomimetic peptide bioregulators including Thymogen in complex treatment of dental diseases and maxillofacial pathology, with particular attention to elderly patients. PMID 32362097 Pinelis IS et al. Advances in gerontology (2020)
- Thymus-pineal gland interaction and geroprotection Mixed
- Review comparing geroprotective effects of thymic peptides (including Thymogen) vs. pineal peptides on organ involution. Pineal peptides showed more effective geroprotective effect on thymus involution than thymic peptides showed on pineal involution. PMID 21809618 Lin'kova NS et al. Advances in gerontology (2011)
- Review noting that thymic peptides (thymalin, thymogen) had comparatively lesser geroprotective effect on pineal gland involution compared to pineal peptides on thymus. PMID 21510076 Lin'kova NS et al. Advances in gerontology (2010)
- Prostate cancer adjunct (IM862, closely related Glu-Trp dipeptide) Human RCT
- Phase II double-blind RCT of IM862 (described as a naturally occurring dipeptide with antiangiogenic and immunomodulatory properties) administered intranasally in prostate cancer patients. IM862 did not demonstrate superiority over placebo in prolonging time to PSA progression; no significant toxicities emerged. Note: PMID 17879948 Mao S et al. The Prostate (2007)
Safety signals
- No significant toxicities reported with intranasal administration (IM862, a related Glu-Trp dipeptide) over 6 months in prostate cancer RCT PMID 17879948
- No haemolytic toxicity observed for L-Glu-L-Trp and conjugate derivatives at 200 µM in haemolysis assay PMID 18428206
- No adverse effects specifically attributed to Thymogen reported in pre-surgical elderly RCT; post-operative complications were significantly reduced in the treatment group PMID 21957588
Protocol
No community dose for Thymogen on record yet.
All studies (15)
- PMID 17879948 Human RCT
Prostate cancer adjunct (IM862, closely related Glu-Trp dipeptide) - PMID 20517227 Human observational
Psychiatric/neurological adjunct therapy (obsessive-compulsive and tic disorders) - PMID 32362097 Human observational
Dental and maxillofacial disease management (bioregulatory therapy) - PMID 19355963 Mixed
Immunomodulation / immunostimulation - PMID 21510076 Mixed
Thymus-pineal gland interaction and geroprotection - PMID 21809618 Mixed
Thymus-pineal gland interaction and geroprotection - PMID 21957588 Mixed
Immunomodulation / immunostimulation - PMID 24003726 Mixed
Immunomodulation / immunostimulation - PMID 28102435 Mixed
ACE inhibition and antihypertensive vascular effects (EW dipeptide) - PMID 32058926 Mixed
Chirality-based regulation of immune homeostasis (immunostimulation vs. immunosuppression) - PMID 35408963 Mixed
Immunomodulation / immunostimulation - PMID 38732260 Mixed
Chirality-based regulation of immune homeostasis (immunostimulation vs. immunosuppression) - PMID 18365736 In vitro only
Receptor binding characterisation (macrophages and thymocytes) - PMID 18428206 In vitro only
Oral bioavailability enhancement (lipid/glycosyl conjugation of L-Glu-L-Trp) - PMID 37861903 Animal studies only
Antioxidant and hepatoprotective effects
Frequently asked
What is Thymogen and what is it used for?
Thymogen is a synthetic dipeptide (L-Glu-L-Trp) originally isolated from thymus tissue. Published research has characterised it as an immunostimulatory thymomimetic (PMID 32058926, PMID 38732260). Clinical studies have examined its use in immune restoration before surgery in elderly patients, and reviews describe its investigation as a geroprotector and interferon inducer (PMID 24003726, PMID 19355963). In vitro studies suggest anti-inflammatory effects in monocyte/macrophage models. I can't recommend it for any specific condition — please speak with a licensed healthcare provider.
What dose of Thymogen should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: one randomized controlled trial used intranasal instillation of 100 mg once daily for 7 days pre-operatively in elderly surgical patients. No other explicit human dosing details are available in the reviewed literature.
Can I take Thymogen orally?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: L-Glu-L-Trp is described as highly hydrophilic with low membrane permeability, which limits oral bioavailability in its native form. Researchers have investigated lipid and glycosyl conjugates to enhance oral absorption in Caco-2 cell models and rat studies, but these modified forms have not been validated clinically. The human clinical studies available used intranasal administration (PMID 21957588, PMID 17879948). Please consult a licensed healthcare provider.
Is Thymogen the same as Bestim or IM862?
These are related but distinct peptides. Thymogen is L-Glu-L-Trp. Bestim is described as gamma-D-Glu-L-Trp — a diastereomer — and competes with Thymogen for binding sites on macrophages and thymocytes. IM862, tested in a prostate cancer RCT, is described only as 'a naturally occurring dipeptide with antiangiogenic and immunomodulatory properties'; the abstract does not explicitly confirm its sequence as L-Glu-L-Trp. These distinctions are important because stereochemistry dramatically affects biological activity.
What is the difference between Thymogen and Thymodepressin?
Thymogen (L-Glu-L-Trp) is characterised in the literature as an immunostimulant, while Thymodepressin (D-Glu(D-Trp)) is its D-enantiomer-based counterpart and is described as an immunosuppressor — the first reported example of enantiomeric peptide drugs with reciprocal (opposite) biological activities (PMID 38732260, PMID 32058926). This means small changes in chirality completely reverse the immunological effect.
Can I stack Thymogen with other peptides or compounds?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: Thymogen has been examined as a single immunomodulatory agent in human studies and as part of a multi-drug regimen with mexidol and hyperbaric oxygenation in a psychiatric study, but the reviewed literature does not provide safety or efficacy data for combining Thymogen with other peptides.
Is Thymogen FDA-approved or legal to use?
The reviewed scientific literature does not state the current FDA, Health Canada, or WADA regulatory status of Thymogen. It has been described as a drug used primarily in former socialist countries. For current regulatory status, please consult official regulatory agency websites or a licensed healthcare provider.
Does Thymogen have anti-aging effects?
Some reviews describe Thymogen among peptide bioregulators studied for geroprotective applications (PMID 24003726, PMID 21809618, PMID 21510076). However, compared to pineal peptides, thymic peptides including Thymogen showed comparatively lesser effects on pineal gland involution in reviewed comparative studies. No robust human RCT data specifically evaluating anti-aging outcomes for Thymogen are available in the reviewed literature.
Are there any side effects or safety concerns with Thymogen?
Based on the reviewed literature: no significant toxicities were reported with intranasal administration of a related Glu-Trp dipeptide (IM862) over 6 months in an RCT, and no adverse effects were specifically attributed to Thymogen in a pre-surgical elderly patient RCT. L-Glu-L-Trp showed no haemolytic toxicity at 200 µM in vitro. However, long-term human safety data are not available in the reviewed abstracts, and no formal toxicology studies in humans are reported. Please consult a licensed healthcare provider before use.
Where can I buy Thymogen?
I don't recommend vendors or sources. Please consult a licensed provider.